Consistently, our analysis of the TCGA data and previous studies demonstrated that p53 mutations and deletion were associated with cancer invasiveness and poor outcome of HCC patients (Jeng et al., 2000; Liu et al., 2012; Zhan et al., 2013). Here, TP53 is linked to hepatocellular carcinoma.